Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...

Analysts slashed their price targets for the Massachusetts biotech after ‘messy’ trial results in alopecia and eczema.

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.

Fintel reports that on December 11, 2024, Wells Fargo downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 1,360.58% Upside As of ...

Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on Q32 Bio (QTTB – Research Report), with a price target of ...

Fintel reports that on December 11, 2024, Leerink Partners downgraded their outlook for Q32 Bio (NasdaqGM:QTTB) from Outperform to Market Perform. Analyst Price Forecast Suggests 260.75% Upside As of ...

After a mid-stage failure in atopic dermatitis, Q32 Bio plans to take bempikibart forward in alopecia instead, despite a trial in that indication also coming apart due to an error in patient ...

Short interest in Q32 Bio Inc (NASDAQ:QTTB) increased during the last reporting period, rising from 678.64K to 686.07K. This put -% of the company's publicly available shares short. Short interest ...

ADHD is one of many neurodivergent conditions, along with autism, dyslexia, Tourette syndrome and others. Although one in ...

Suspect in C.E.O.’s Killing Fights Extradition to New York Police say suspect in the United Healthcare killing saw himself as a hero fighting corruption. The suspect had discussed a series of ...